Headache & Pain

Filter Your Results




Free Resource for People Living With Migraine—Migraine Patient Guidelines

Tuesday, April 16, 2019—A new publication for people living with migraine, Migraine Patient Guidelines from The Global Healthy Living Foundation, is available for free download to assist pe…

Clinical Trial Begins for Third-Generation CGRP-Antagonist Nasal Spray for Acute Migraine Treatment

Tuesday, April 02, 2019—The first patient has been enrolled in a phase 2/3, double-blind, placebo-controlled trial of intranasally administered BHV-3500 (Biohaven Pharmaceutical, New Haven, CT) being…

Many Patients Who Start Botulinum Toxin for Migraines Discontinue Treatment Early

Wednesday, March 27, 2019—A real-world study revealed that less than half of patients who begin treatment with onabotulinumtoxinA (Botox; Allergan, Madison, NJ) to prevent chronic migraine receive all …

New Drug Application Accepted for Ubrogepant for Acute Migraine Treatment

Monday, March 11, 2019—The Food and Drug Administration (FDA) has accepted the new drug application (NDA) for ubrogepant for acute migraine treatment (Allergan, Madison, NJ) and set a 10-month …

FDA Grants Priority Review to Galcanezumab for Prevention of Cluster Headache

Wednesday, March 06, 2019—The Food and Drug Administration (FDA) has granted priority review status to the supplemental biologics license application (sBLA) for galcanezumab-gnlm (Emgality; Eli Lilly a…

FDA Provides Expanded Clearance for Device to Treat Migraine in Children

Thursday, February 28, 2019—The Food and Drug Administration (FDA) has granted new marketing clearance for a device that provides acute and preventive treatment of migraine to include children 12 years o…

FDA Clears Radio Frequency Nerve Tissue Ablation System for Treatment of Pain

Wednesday, February 27, 2019—The Food and Drug Administration (FDA) has cleared a radiofrequency (RF) nerve ablation system (Accurian; Medtronic, Dublin, Ireland) for the treatment of patients with chroni…

Nasally-Delivered CGRP Antagonist for Migraine Achieves Phase 1 Clinical Trial Targets

Wednesday, February 06, 2019—In a phase 1 clinical trial, it was shown that intranasal delivery of a third-generation calcitonin gene-related peptide antagonist reached therapeutic levels in treated parti…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.